ASMB

Assembly Biosciences, Inc.
CAPPED RATING

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Assembly Biosciences, Inc. (ASMB) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Growth (D). The rating has held at C for 4 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
B-
Factor Score 3.0 / 5.0
Growth
D
Factor Score 1.2 / 5.0
Profitability
C
Factor Score 2.4 / 5.0
Momentum
D+
Factor Score 1.7 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 28.0
EV / EBITDA -5.8
Rev Growth YoY -72.6%
Gross Margin -0.4%
Price Return 3M -33.7%
Price Return 12M -40.1%
Catalyst Signal 0.00
Market Cap $436.0M
TTM Revenue $67.0M
Price / Sales 6.5
ROE -4.6%

Historical Factor Score Progression

Held C for 4 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 B- (3.0) D (1.2) C (2.4) D+ (1.7) C+ (2.6) C (2.2)
2026-11-10 B- (3.1) C- (2.0) C+ (2.5) C- (2.1) C+ (2.6) C (2.5)
2026-11-03 B- (3.1) C- (2.0) C+ (2.6) C- (2.0) C+ (2.7) C (2.5)
2026-10-27 B- (3.1) C- (2.0) C+ (2.6) C- (2.1) C+ (2.6) C (2.5)
2026-10-20 B- (3.1) C- (2.0) C+ (2.6) C- (2.1) C+ (2.6) C (2.5)
Page 1 of 6